MedTrace Logo

131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma

NCT01678404 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-09-05

No results posted yet for this study

Summary

Marginal zone B-cell lymphoma (MZL) is a lymphoma originated from B-cell in lymph node with variable differentiation status, which is distributed to a variety of organs.

A high response rate and long term survival is possible through surgery or radiation therapy alone in the case of limited disease. However frequent relapse and progression is observed despite of long term survival. The treatment after relapse has not been established yet.

So we investigate the efficacy of radioimmunotherapy using 131I-rituximab in refractory or relapsed patients with MZL.

Conditions

  • Relapsed or Refractory Marginal Zone B-cell Lymphoma

Interventions

DRUG

131I-rituximab

Sponsors & Collaborators

  • Korea Cancer Center Hospital

    lead OTHER

Principal Investigators

  • Hye Jin Kang, M.D. · Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2014-09-30
Completion
2016-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01678404 on ClinicalTrials.gov